Impact of tDCS on Cannabis Craving in Schizophrenia
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorCentre hospitalier de Ville-Evrard, France
About this trial
This study aims to evaluate the tDCS's impact on cannabis craving in patients with schizophrenia and cannabis addiction disorder.
Eligibility criteria
Qualifiers
Patients (male or female) aged 18-65
Patients with schizophrenia according to DSM 5 criteria with Comorbid diagnosis of "cannabis use disorder"
conceptual disorganization
distrust
Disqualifiers
Presence of any other psychiatric disorder, as per DSM-5 criteria.
Pregnancy, possible pregnancy due to lack of contraception, breastfeeding.
Currently active suicidal or self-injurious ideation (suicidal or not)
Patients with Serious medical codition
Trial design
Treatments tested in this trial
- tDCS
Treatment groups
138 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov